Imipramine

Lore & Background

Imipramine, first synthesized in 1951 and introduced for medical use in 1957, holds the distinction of being the first tricyclic antidepressant (TCA) brought to market. It is administered orally. The drug functions by elevating levels of serotonin and norepinephrine while also blocking certain serotonin, adrenergic, histamine, and cholinergic receptors. Its primary applications include the treatment of depression and specific anxiety disorders, such as acute post-traumatic stress reactions. Research into its use for acute trauma in children and adolescents has notably involved cases of burn injuries, though evidence for chronic post-traumatic stress disorder is less robust. Imipramine is also employed for nocturnal enuresis, as it shortens delta wave sleep stages when bedwetting occurs. In veterinary medicine, it is used with xylazine to induce ejaculation in stallions and for separation anxiety in dogs and cats. Common side effects encompass dry mouth, drowsiness, dizziness, low blood pressure, rapid heart rate, urinary retention, and electrocardiogram changes. Overdose can be fatal. Its prescription has declined with the rise of SSRIs, which generally have more tolerable side effects and are safer in overdose, yet imipramine retains importance in psychopharmacology and pediatrics. Caution is necessary when prescribing to children and adolescents due to the risk of accidental overdose.

Reader's Guide

Imipramine, discovered in 1951 and introduced for medical use in 1957, was the first tricyclic antidepressant (TCA) to be marketed. It is taken by mouth and primarily used to treat depression, anxiety, and panic disorder, with demonstrated efficacy similar to the MAOI moclobemide in depression. It also treats nocturnal enuresis by shortening delta wave stage sleep, where wetting occurs. In veterinary medicine, it is used with xylazine to induce ejaculation in stallions and for separation anxiety in dogs and cats. The drug appears to work by increasing serotonin and norepinephrine levels while blocking certain serotonin, adrenergic, histamine, and cholinergic receptors. Blood levels of imipramine plus its metabolite desipramine between 150 and 250 ng/mL generally correspond to antidepressant efficacy. Common side effects include dry mouth, drowsiness, dizziness, low blood pressure, rapid heart rate, urinary retention, and ECG changes; overdose can be fatal. It has many medication interactions, including serious ones with MAOIs, and caution is needed in children due to accidental overdose risk. Despite decreased prescription frequency with the rise of SSRIs—which have more tolerable side effects and are safer in overdose—imipramine retains importance in psychopharmacology and pediatrics, particularly for childhood enuresis.

Did You Know?

• It is used in veterinary medicine with xylazine to induce pharmacologic ejaculation in stallions.
• Imipramine is converted in the body into desipramine as a metabolite.
• Combining imipramine with alcohol may cause more drowsiness.

Pioneering the Tricyclic Era

Imipramine, marketed under the brand name Tofranil among others, holds a distinguished place in the history of psychiatric medicine. Discovered in 1951 and brought into clinical use in 1957, it became the very first tricyclic antidepressant to reach the market, opening an entirely new pharmacological pathway for treating depression. For decades it anchored the TCA class that would dominate antidepressant therapy before the next generation of drugs arrived. Today its prescription frequency has waned considerably, largely because selective serotonin reuptake inhibitors offer a more forgiving side-effect profile and carry far less risk in the event of an accidental or intentional overdose. Nevertheless, imipramine has not faded from relevance. It continues to occupy a meaningful niche in psychopharmacology and, notably, in pediatric practice—where it remains a recognized option for conditions such as childhood enuresis. Its legacy as the drug that proved a chemical intervention could alleviate the suffering of major depression remains foundational to how we understand and treat mood disorders.

A Multi-Target Pharmacological Profile

At the molecular level, imipramine exerts its therapeutic effects by simultaneously engaging several neurotransmitter systems. As a tertiary tricyclic antidepressant, it is a particularly potent inhibitor of serotonin reuptake, outperforming secondary-amine TCAs such as nortriptyline and desipramine in that regard. It also strongly inhibits norepinephrine reuptake, though its metabolite desipramine shows greater affinity for the norepinephrine transporter. Beyond monoamines, imipramine blocks D2 dopamine receptors, acts as a relative muscarinic antagonist contributing to anticholinergic effects, and modulates histamine and adrenergic receptors. This broad receptor footprint explains both its efficacy and its wide-ranging side effects. Interestingly, its structural resemblance to certain muscle relaxants endows it with a notable analgesic quality, making it useful in select pain conditions. The drug's influence spans systems implicated in depression, anxiety, ADHD, enuresis, and other mental and physical ailments, reflecting the complexity of the conditions it addresses.

Clinical Reach Beyond Major Depression

While imipramine is best known as an antidepressant, its therapeutic applications extend well into adjacent psychiatric and even veterinary territory. In anxiety and panic disorders it has demonstrated meaningful benefit, and research has specifically explored its role in acute post-traumatic stress reactions, with a notable body of evidence drawn from pediatric burn-injury populations. For chronic PTSD the evidence is somewhat less compelling, yet the drug remains a viable option, with efficacy that may parallel that of the MAOI phenelzine. In the treatment of depression itself, imipramine has shown comparable effectiveness to the MAOI moclobemide. A particularly distinctive use is nocturnal enuresis in children, where the drug shortens the delta-wave sleep stage during which bed-wetting typically occurs. In veterinary medicine, imipramine combined with xylazine is employed to induce pharmacologic ejaculation in stallions, and it is also prescribed for separation anxiety in dogs and cats. Therapeutic blood levels of imipramine plus its metabolite desipramine generally fall between 150 and 250 ng/mL for antidepressant effect.

Safety Considerations and Drug Interactions

The very breadth of imipramine's receptor activity translates into a substantial side-effect burden. Common complaints include dry mouth, drowsiness, dizziness, orthostatic hypotension, tachycardia, urinary retention, and electrocardiogram changes, while rarer but serious effects span seizures, agranulocytosis, jaundice, and extrapyramidal symptoms in older adults. Perhaps most critically, an overdose of imipramine can be fatal, a concern amplified in pediatric populations and a key reason its use in children and adolescents demands careful monitoring. The drug's interaction profile is extensive. Co-administration with MAOIs—whether isocarboxazid, phenelzine, moclobemide, or others—is contraindicated during treatment and for two weeks after discontinuation due to the risk of severe reactions. Alcohol deepens sedation, tobacco can diminish the drug's effectiveness, and combinations with SSRIs, St. John's Wort, or substances like ecstasy raise the specter of serotonin syndrome. Additional caution is warranted with blood thinners, antihistamines, muscle relaxants, barbiturates, and certain antiepileptic or HIV protease-inhibitor drugs, all of which can alter imipramine's levels or cardiac effects.

Gallery